RTW Investments LP Sells 2,148,494 Shares of ESSA Pharma Inc. (NASDAQ:EPIX)

RTW Investments LP cut its stake in shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) by 65.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,113,002 shares of the company’s stock after selling 2,148,494 shares during the quarter. RTW Investments LP owned 2.51% of ESSA Pharma worth $1,992,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Two Sigma Securities LLC purchased a new stake in ESSA Pharma during the 4th quarter valued at about $29,000. FNY Investment Advisers LLC purchased a new stake in ESSA Pharma during the 4th quarter valued at about $44,000. Cubist Systematic Strategies LLC purchased a new stake in ESSA Pharma during the 4th quarter valued at about $47,000. Lepercq Multi Asset Fund purchased a new stake in ESSA Pharma during the 4th quarter valued at about $54,000. Finally, XTX Topco Ltd purchased a new stake in ESSA Pharma in the 4th quarter worth approximately $67,000. 75.12% of the stock is currently owned by hedge funds and other institutional investors.

ESSA Pharma Stock Performance

NASDAQ EPIX opened at $1.71 on Friday. ESSA Pharma Inc. has a fifty-two week low of $1.40 and a fifty-two week high of $7.88. The stock has a 50 day simple moving average of $1.65 and a two-hundred day simple moving average of $1.77. The stock has a market cap of $75.91 million, a P/E ratio of -2.48 and a beta of 1.69.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.05. Sell-side analysts predict that ESSA Pharma Inc. will post -0.42 earnings per share for the current year.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.